Therapeutic Area: Urology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Urovant Sciences a family company of Sumitovant announced the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder from two Phase 1 trials.